Vaccines

((SLC-049)) (SLC-049) Risk of Atrial Fibrillation After Bivalent COVID-19 Vaccination During the 2022-2023 Season

((SLC-050)) (SLC-050) Effectiveness of booster (third-dose) COVID-19 vaccination during pregnancy: a target trial emulation study using 4 European databases

((SLC-051)) (SLC-051) A Pregnancy Registry to Evaluate the Safety of CYD Tetravalent Dengue Vaccine among Inadvertently Exposed Pregnant Women and their Offspring

((SLC-052)) (SLC-052) Safety Evaluation of Multiple Vaccination Regimens for the Elderly in Japan: The VENUS Study

((SLC-053)) (SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study

((SLC-054)) (SLC-054) Risk factors for myocarditis/pericarditis following mRNA-1273 vaccination: interim analysis of a VAC4EU case-cohort study

((SLC-055)) (SLC-055) Clinical course and outcomes of myocarditis/pericarditis cases following mRNA-1273 vaccination compared to cases not following COVID-19 vaccination: interim analysis of a VAC4EU cohort study

((SLC-056)) (SLC-056) COVID-19 vaccine effectiveness against Post COVID-19 condition among 1,292,557 individuals with pre-existing immunity against SARS-CoV-2: a population-based cohort study.

((A-329)) (A-329) Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023–2024 Season among U.S. individuals aged 6 months through 64 years

((A-330)) (A-330) Type 1 Diabetes Mellitus in Individuals Receiving COVID-19 Messenger RNA Vaccination

((A-331)) (A-331) Safety Monitoring of Multiple Health Outcomes following 2023–2024 COVID-19 Vaccination among Commercial Health Plan Enrollees Aged 6 Months–64 Years in the United States

((A-332)) (A-332) Monitoring safety of Moderna COVID-19 vaccines in pregnancy: a multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated postauthorisation safety study in the VAC4EU network (EUPAS44450).

((A-333)) (A-333) Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis

((A-334)) (A-334) Incidence rates of safety outcomes in a post-approval study of the Pfizer-BioNTech monovalent COVID-19 vaccine in the United States, booster dose analysis

((A-335)) (A-335) Leveraging Real-World Data for Regulatory Commitment: Methodological Considerations in a Post-Approval Safety Study Evaluating the Risk of Atrial Fibrillation (AF) Following Respiratory Syncytial Virus (RSV) Vaccination

((A-336)) (A-336) Regional differences in COVID-19 vaccine uptake and their determinants among Swedish older adults

((A-337)) (A-337) Dependence of the Data Source on the Positive Predictive Value in the Retrospective Case Validation of Thrombosis and Thrombocytopenia Syndrome cases using Real-World Data

((A-338)) (A-338) Evaluating the Diagnostic Accuracy of Adverse Events of Special Interest Following Janssen COVID-19 Vaccine (JCOVDEN) Using the VAC4EU Validation Pipeline

((A-339)) (A-339) 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe

((A-340)) (A-340) Characterizing background risk of febrile seizure among pediatric patients during routine clinical care and vaccination

((A-341)) (A-341) Incidence of herpes zoster and vaccination rates in VA long-stay nursing home residents

((A-342)) (A-342) Safety of COVID-19 vaccination among patients with autoimmune diseases in Korea: a population-based self-controlled case series study

((A-343)) (A-343) Developing the Framework of Epidemiological and Biostatistical Approaches for Post-Approval Vaccine Safety Assessment Using a Large Healthcare Database in Japan: Year 1 Progress

((A-344)) (A-344) Opportunities and Challenges of Using Brazilian Databases in Vaccine Pregnancy Registry Studies

((A-345)) (A-345) Assessment of the Safety of Human Papillomavirus Vaccination in Japan: VENUS Study

((A-346)) (A-346) Background Rates of Adverse Events for Vaccine Safety Monitoring at Two Sentinel Hospitals in Addis Ababa, Ethiopia

((A-347)) (A-347) Patient and Epidemiological Factors Associated with Respiratory Syncytial Virus (RSV) Testing in Adults Hospitalized with RSV-Like Illness, 2023–2024 Respiratory Season

((A-348)) (A-348) Incidence of human metapneumovirus among older adults in 10 high-income countries: a systematic literature review, meta-analysis, and modeling study

((A-349)) (A-349) Assessing the Association Between COVID-19 Vaccination and Thrombotic Thrombocytopenia Syndrome (ATTEST Study): Analyses of English Data, 2020–2022

((A-350)) (A-350) Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results From an Interim Analysis

((A-351)) (A-351) Autoimmune Disease Risks Across COVID-19 Vaccine Platforms: A Population-Based Cohort Study in Taiwan

((A-352)) (A-352) Barriers and Strategies to Improve Vaccine Adverse Events Reporting: Views from Health Workers and Managers in Northern Ghana

((A-353)) (A-353) Application of the Actor-Partner Interdependence Model to Understand COVID-19 Vaccine Decision-Making among Adolescents and their Parents

((A-354)) (A-354) Methods for Estimating Background Rates of Obstetric and Adverse Events of Special Interest During Pregnancy: A Multi-Site Analysis of Over 3 Million Annual Births

((A-355)) (A-355) Post-marketing safety surveillance for bivalent human papillomavirus vaccine in a regional healthcare database in China

((A-356)) (A-356) Safety Profile of Vaxzevria® COVID-19 Vaccine in the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)

((A-357)) (A-357) Assessment of the Risk of 32 Adverse Effects of Special Interest following COVID-19 Vaccination in the Whole French Population

((A-358)) (A-358) Using Tree-Based Scan Statistics to Monitor Routine Vaccines for Possible Associations with Guillain-Barré Syndrome in the Vaccine Safety Datalink

((A-359)) (A-359) Vaccine-related studies listed in the Heads of Medicines Agencies-European Medicines Agency (HMA-EMA) Catalogue of Real-World Data studies: What can we learn from study characteristics?

((A-360)) (A-360) Social Disparities in HPV Vaccination Uptake Among Adolescent Girls in France (2007–2023)

((A-361)) (A-361) Vaccinia vaccine effectiveness against mpox virus infections: a living literature review and evidence synthesis

((B-308)) (B-308) Safety Monitoring of Mpox Vaccines in Adults Aged 18–64 Years during the 2022 Mpox Outbreak in the U.S.

((C-253)) (C-253) Active and Passive Safety Surveillance in Children Receiving Fluenz® Tetra Vaccination in England During Influenza Seasons - from 2014/2015 to 2022/2023

((C-254)) (C-254) Concomitant COVID-19 and Influenza Vaccination and the Risk of Psychiatric Adverse Events: a nationwide self-controlled case series study

((C-255)) (C-255) Assessing Knowledge, Attitude and Practice on Human Papilloma Virus Vaccination Among Medical Students at the University of Nairobi

(C-256) Validation of Guillain-Barré Syndrome case identification in 4 heterogeneous real-world data sources in Spain and the United Kingdom using the Brighton Collaboration criteria.